Effects of hormone replacement therapy on selected indices of immune function in postmenopausal women

Gynecologic and Obstetric Investigation

Volumn 50, Issue 3, 2000, Pages 189-193

  Fahlman, Mariane M ^a   Boardley, Debra ^f   Flynn, Michael G ^b   Bouillon, Lucinda E ^c   Lambert, Charles P ^d   Braun, William A ^e  

^a WAYNE STATE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF FINDLAY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^f NONE

Author keywords

Estrogen; Immune function; Lymphocyte proliferation; Natural cell mediated cytotoxicity; Postmenopausal hormone replacement

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; CELL COUNT; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MONONUCLEAR CELL; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0033807439     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010308     Document Type: Article

References (29)

1. Bush TL, Barrett-Conner E, Cowan LD: Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics' Program follow-up study. Circulation 1987;75:1102-1109.
2. Henderson BE, Paganni-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-81.
3. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
4. Stampfer MJ, Colditz GA, Willet WC: Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow-up from the Nurses' Health Study. N Engl J Med 1991;325: 756-762.
5. Malone KE, Darling JR, Weiss NS: Oral contraceptives in relation to breast cancer risk. Epidemiol Rev 1993;15:80-97.
6. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:314-323.
7. Brinton LA, Schairer C: Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993;15:66-79.
8. Tremollieres FA, Strong DD, Baylink D, Mohan S: Progesterone and promogesterone stimulate human hone cell proliferation and insulin-like growth factor 2 production. Acta Endocrinol (Copenh) 1992;126:329-337.
9. Baker DA, Salvator W, Milch PO: Effect of low-dose oral contraceptices on natural killer cell activity. Contraception 1989;39:119-124.
10. Bunyon JP, Korchak HM, Rutherford LE, Ganguly M, Weissmann G: Female hormones reduce neutrophil responsiveness in vitro. Arthritis Rheum 1984;27:623-630.
11. Ferguson MM, McDonald FG: Oestrogen as an inhibitor of human NK cell cytosis. FEBS Lett 1985;191:145-148.
12. Myers MJ, Petersen BH: Estradiol induced alteration of the immune system. 1. Enhancement of IgM production. Int J Immunopharmacol 1985;7:207-213.
13. Myers MJ, Butler LD, Pedersen BH: Estradiol-induced alteration in the immune system. II. Suppression of cellular immunity in the rat is not the result of direct estrogenic action. Immunopharmacology 1986;11:47-55.
14. Grossman CJ: Regulation of the immune system by sex steroids. Endocr Rev 1984;5:435-455.
15. Burleson MH, Malarkey WB, Cacioppo JT, Poehlmann KM, Kiecolt-Glaser JK, Berntson GG, Glaser R: Postmenopausal hormone replacement: Effects on autonomic, neuroendocrine, and immune reactivity of brief psychological stressors. Psychosom Med 1998;60:17-25.
16. Whitlock EP, Johnson RE, Vogt TM: Recent patterns of hormone replacement therapy use in a large managed care organization. J Women's Hlth 1998;7:1017-1026.
17. Brunelli R, Frasca D, Perrone G, Pioli C, Fattorossi A, Zichella L, Doria G: Hormone replacement therapy affects various immune cell subsets and natural cytotoxicity. Gynecol Obstet Invest 1996;41:128-131.
18. Weintraub MS, Grosskopf I, Charach G, Eckstein N, Ringel Y, Mararshak N, Rotmensch HH: Fluctuations of lipid and lipoprotein levels in hyperlipidemic postmenopausal women receiving hormone replacement therapy. Arch Intern Med 1998;158:1803-1806.
19. Baron GC, Klimas NG, Fischl MA, Fletcher MA: Decreased natural cell-mediated cytotoxicity per effector cell in acquired immunodeficiency syndrome. Diagn Immunol 1985;3:197-204.
20. Fletcher MA, Baron GC, Ashman MR, Fischl MA, Klimas NG: Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn Clin Immunol 1987; 5:69-81.
21. Paavonen T, Anderson LC, Adlercreutz H: Sex hormone regulation of the in vitro immune response. J Exp Med 1981;154:1935-1945.
22. Sanche-Guerrero J, Liang MH, Karlson EW: Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-433.
23. Sthoeger ZM, Chiorazzi N, Lahita RG: Regulation of the immune system by sex hormones. J Immunol 1988;141:91-98.
24. Seaman VE, Ginghart TD: Effects of estrogens on natural killer cells. Arthritis Rheum 1979; 22:1234-1238.
25. Coleman RM, Lombard MF, Sicard RE: In Wheatley CH (ed): Fundamental Immunology. Dubuque, William C Brown, 1992.
26. Kuby J: Immunology. New York, Freeman, 1994.
27. Mackinnon LT: Exercise and Immunology. Champaign, Human Kinetics, 1992.
28. Schindler LW: Understanding the Immune System. Washington, National Institute of Health, 1993.
29. Taskinen M-R: Oestrogen replacement therapy and coronary heart disease. Ann Med 1998;30: 443-451.